Monoclonal Antibody
Fewer hospitalizations, death with neutralizing monoclonal antibodies for COVID-19
Treatment with neutralizing monoclonal antibodies in COVID-19 outpatients resulted in fewer hospital admissions and deaths vs. no antibody treatment, according to results published in CHEST.
FDA approves monoclonal antibody to prevent RSV in infants
The FDA on Monday approved a monoclonal antibody for the prevention of respiratory syncytial virus lower respiratory tract disease in newborn and infants.
Part of the Healio Network
PCSK9 Inhibitors Topic Review
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protein that binds to the LDL receptor on hepatocytes, promoting its internalization and degradation within the cell. [Repatha package insert;9a]
FDA advisors recommend monoclonal antibody to protect infants from RSV
An FDA advisory committee on Thursday voted in favor of approving the long-acting monoclonal antibody nirsevimab to protect neonates and infants from respiratory syncytial virus.
VIDEO: Low risk for congestive heart failure exacerbation with Zinplava for C. difficile
CHICAGO — In this Healio video exclusive, Paul Feuerstadt, MD, FACG, AGAF, recaps results from a real-world analysis of Zinplava for prevention of recurrent Clostridioides difficile infection in patients with congestive heart failure.
Monoclonal antibody speeds time to HIV viral suppression, study finds
A monoclonal antibody was shown to speed the time to viral suppression in heavily treatment-experienced people with HIV compared with ART regimens that did not contain it, according to a study.
Monoclonal antibodies significantly reduced risk for COVID-19 hospitalization, death
Treatment with a monoclonal antibody within 2 days of a COVID-19 diagnosis reduced the risk for hospitalization or death by almost 40%, according to a study that assessed patient outcomes over a nearly 2-year period.
Eli Lilly’s novel eltrekibart shows early promise in hidradenitis suppurativa
NEW ORLEANS — A novel monoclonal antibody could be a promising treatment for hidradenitis suppurativa as phase 2 clinical trial results showed an improvement in total abscess and nodule count after 16 weeks of treatment.
First biosimilar monoclonal antibody for MS shown to be safe, effective in phase 3 trial
PB006, the first biosimilar for natalizumab, showed comparable safety, efficacy and immunogenicity to the reference monoclonal antibody therapy in patients with relapsing-remitting MS, researchers wrote in JAMA Neurology.
Tislelizumab regimen new first-line option for gastric, gastroesophageal cancer subgroup
Tislelizumab plus chemotherapy demonstrated statistically significant and clinically meaningful improvements in OS vs. chemotherapy alone among patients with PD-L1-positive, advanced gastric or gastroesophageal junction adenocarcinoma.